# Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

> **NCT06039371** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 69 (estimated)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Etoposide
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Testosterone Cypionate
- **OTHER:** Radioconjugate
- **PROCEDURE:** Dual X-ray Absorptiometry
- **OTHER:** Gallium Ga 68-PSMA-617
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Single Photon Emission Computed Tomography

## Key facts

- **NCT ID:** NCT06039371
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039371, "Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06039371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*